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Abstract 
Genetic defects causing uncontrolled complement activation are associated with aHUS. Non-
EHEC infections can trigger the disease, however, complement defects predisposing to such 
infections have not yet been studied. 
We describe a two-month old patient infected with different Gram-negative bacterial species 
resulting in aHUS. Serum analysis revealed slow complement activation kinetics. Rare variant R229C 
was found in complement inhibitor vitronectin. Recombinant mutated vitronectin showed enhanced 
complement inhibition in vitro and may have been a predisposing factor for infection.  
Our work indicates that genetic changes in aHUS can not only result in uncontrolled 
complement activation but also increase vulnerability to infections contributing to aHUS.  
 Key words: atypical HUS, complement inhibition, infection, mutation, vitronectin  
 
  3
Introduction 
Hemolytic uremic syndrome (HUS) is a devastating renal disease, which is characterized by 
hemolytic anemia, thrombocytopenia and acute renal failure. Most HUS cases are caused by infection 
with enterohemorrhagic Escherichia coli (EHEC). However, 5-10% of HUS patients have a more 
severe atypical form (aHUS). Overactive complement is considered to be a central element in aHUS 
pathogenesis1. 
The complement system, a part of the innate immune system, can be activated via three 
pathways: the classical, the lectin and the alternative. These pathways converge at the cleavage and 
activation of the central complement component C3 leading further to formation of the terminal C5b-9 
complement complex (TCC) and release of the potent anaphylatoxins C3a and C5a1. 
Sequence variants that lead to impaired complement regulation of C3 activity in aHUS are 
found in genes encoding CFH, CFI, MCP, C3, CFB and thrombomodulin. Moreover, important C3 
convertase inhibitor CFH can be affected by autoantibodies (anti-CFH)1. Next to these abnormalities, 
aHUS episodes can sometimes be triggered by non-EHEC infections, including Streptococcus 
pneumoniae, Pseudomonas aeruginosa, influenza A, HIV and others1,2. Several cases of infection with 
Bordetella pertussis have also been reported3-5. The infections trigger initial complement attack, which 
cannot be adequently controlled due to dysregulating genetic changes and may cause renal damage 
in aHUS. Nevertheless, genetic predisposition to infections in aHUS has not yet been studied.  
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 Case report 
A female infant was diagnosed with whooping cough at the age of seven weeks. The presence 
of Bordetella pertussis infection was confirmed by serological analysis, where IgG values increased 
from 1 Virotech unit (VE)/mL to 10 VE/mL in first eight days of the disease. At day 10 after the onset of 
infection, the patient developed acute renal failure (serum creatinine 257 µmol/L, urea 27.5 mmol/L), 
hemolytic anemia (Hb 2.8 mmol/L, LDH 3591 U/L) and mild thrombocytopenia (platelets 147*109/L) 
and was consequently diagnosed with aHUS. Infection with EHEC O157 was excluded by fecal culture 
and PCR. ADAMTS13 activity was normal (53%), which excluded thrombotic thrombocytopenic 
purpura. At this time the patient also developed pneumonia (sputum positive for Moraxella catarrhalis) 
and sepsis (Klebsiella oxytoca in blood). The infant received blood transfusions, continuous veno-
venous hemofiltration (CVVH) and was venilated. She recovered completely from the aHUS 10 days 
later (20 days after the onset of the pertussis) with normalized renal function (serum creatinine 43 
µmol/L, urea 1 mmol/L). During a 10 year follow-up, patient presented no other episode of aHUS or 
severe infection.   
Due to infections with Gram-negative bacteria, we analyzed activity of the three complement 
pathways after the patient had recovered from aHUS. These were within the normal range (Table 1). 
The in vitro complement activation of patient serum was compared to that of normal human serum 
(NHS). In patient’s serum C3 activation rate (expressed as generation of C3bc) was comparable to the 
rate in NHS, but the TCC generation was delayed (Figure 1 A and B).  
Genetic screening of the alternative pathway indicated presence of a heterozygous missense 
variant in thrombomodulin (A43T), which was previously described as pathogenic in aHUS6. No other 
changes in alternative pathway or anti-CFH autoantibodies were detected. 
Because kinetic experiments have shown decreased rate of TCC generation, we analyzed the 
patient for possible defects in genes encoding TCC components and TCC inhibitors (vitronectin, 
clusterin and CD59). A heterozygous variant rs782409757:c.685C>T (R229C) was found in gene 
encoding vitronectin. In silico analysis indicated this variant as deleterious (SIFT score 0.0) and 
probably damaging (PolyPhen-2 score 1.0) as a large positively charged amino acid is replaced by an 
unpaired cysteine. Patient vitronectin plasma levels were normal (Table 1). In vitro experiments using 
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purified recombinant proteins revealed that mutant vitronectin was more potent in complement 
inhibition compared to the wild type (Figure 1C).  
The c.685C>T (R229C) is a rare variant, reported with the frequency of 0.0015% in European 
population (http://exac.broadinstitute.org/variant/17-26696034-G-A). Moreover, we tested the variant in 
390 Dutch children who survived bacterial meningitis, since variation in innate immune response 
genes also affects susceptibility to meningitis7. None of the children had the vitronectin variant, which 
may be explained by low incidence of the change. 
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 Discussion 
In this work we presented a case of aHUS in a two-month old infant. Although B. pertussis 
aHUS cases have been described before, to our knowledge, this is the first case associated with 
simultaneous isolation of K. oxytoca and M. catarrhalis.   
 Functional assessment of the complement system did not reveal major abnormalities (Table 
1). Low functional activity of MBL-mediated lectin pathway was found, which is very common in the 
human population thus not considered as defect. In our previous work we have found that MBL 
deficiency is not more common in aHUS patients than in healthy controls8. 
The rate of TCC formation in patient’s serum was slower than in the NHS. This is in line with 
less efficient lysis of sheep erythrocytes by the TCC complex, assembled from purified components in 
the presence of recombinant vitronectin with R229C mutation. Delayed TCC response may have 
caused inefficient initial clearance of Gram-negative bacteria in the patient, which resulted in infection 
and profound complement activation. Due to the presence of thrombomodulin change, complement 
attack was poorly contolled at the level of C3 activation with aHUS episode as a result.  
  Importantly, aHUS patients are currently treated with TCC blocker eculizumab. Patients that 
carry TCC inhibiting variants, as for the fitst time described here, may require lower drug doses. 
Taken together, our work indicates that a genetic cause may contribute to aHUS not only by a 
well-known effect of complement dysregulation, but also by enhancing vulnerability to infections during 
early infancy.  
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Table 1. Complement activity assessment in aHUS patient. 
Complement pathway Patient’s value Reference range 
   
Classical pathway (%)1 77.4 69-129 
Alternative pathway (%)1 75.1 30-113 
Lectin pathway (MBL-mediated) (%)1 18.2 0-125 
   
Plasma vitronectin concentration (µg/mL)2 
 
190   185-5954 (286, n=20)3 
 
1Measured using Wieslab® Complement system Screenkit (Euro Diagnostica) and given as 
percentage of the positive control, provided with the assay. Reference range is presented as indicated 
by the manufacturer. 
2 Measured using Human Vitronectin Total ELISA Kit (Innovative Research). 
3 Reference range was determined as range of values, measured in a healthy control group, median 
value and number of analyzed controls are indicated in parenthesis. 
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Figure legends 
Figure 1. A. Serum of patient carrying R229C mutation in vitronectin and normal human serum pool 
(NHS) were incubated at 37°C with gentle agitation. Samples were collected at 0, 10, 20, 30 and 60 
minutes of incubation and C3bc levels were quantified in complement activation units per mL 
(CAU/mL) using international complement standard #29. Data were collected in three independent 
experiments and presented as mean± standard error. B. TCC levels were quantified in the same 
experimental set up as C3bc9. C TCC was allowed to form on the surface of sheep erythrocytes from 
purified components of (C5b6, C7, C8, C9) as previously described10 in the presence of various 
concentrations of purified recombinant vitronectin variants. The wild type (rVTN wt) and mutant (rVTN 
R229C) vitronectin variants (amino acids 20-396) were produced in HEK293T cells as previously 
described11. Efficiency of TCC formation was quantified as percentages of lysed erythrocytes. Data 
were collected in four independent experiments and presented as mean+ standard error. 
 
 
 

